Recent publications published by researchers at the MRC WIMM.
Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice
Mukhopadhyay E. et al, (2025), Frontiers in Immunology, 16
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman N. et al, (2025), Lancet Microbe, 6
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
Reinke S. et al, (2023), Cell Rep Med, 4
Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.
Mukhopadhyay E. et al, (2022), Biotechnol Bioeng, 119, 2784 - 2793
Virus-like particle vaccines
Mukhopadhyay E. et al, (2022), Vaccinology and Methods in Vaccine Research, 163 - 176
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818
Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites.
Kolli SK. et al, (2021), PLoS One, 16
SAFETY AND IMMUNOGENICITY OF WITH NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH MATRIX M1
Venkatraman N. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 95, 123 - 123
SAFETY, IMMUNOGENICITY AND DURABILITY OF A NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH AS01B
Venkatraman N. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 97, 132 - 132